Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov. The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov. The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts. Notice Enter a search term or FR citation e.g. 88 FR 38230 FR 78782024-13208USDA09/05/24RULE0503-AA39SORN Choosing an item from full text search results will bring you to those results. Pressing enter in the search box will also bring you to search results. Choosing an item from suggestions will bring you directly to the content. The announcement of the availability on FDA's website of the final order is published in the Federal Register on June 10, 2026. Table of Contents Enhanced Content - Table of Contents This table of contents is a navigational tool, processed from the headings within the legal text of Federal Register documents. This repetition of headings to form internal navigation links has no substantive legal effect. This PDF is FR Doc. 2026-11578 as it appeared on Public Inspection on 06/09/2026 at 8:45 am. It was viewed 8203 times while on Public Inspection. If you are using public inspection listings for legal research, you should verify the contents of the documents against a final, official edition of the Federal Register. Only official editions of the Federal Register provide legal notice of publication to the public and judicial notice to the courts under 44 U.S.C. 1503 & 1507. Learn more here. Published Document: 2026-11578 (91 FR 35220) This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format. AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. SUMMARY: In response to an over-the-counter (OTC) monograph order request (OMOR), the Food and Drug Administration (FDA) is announcing the availability on its website of the final administrative order (final order) (OTC000039) titled “Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information.” This final order amends “Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use” (OTC Monograph M020) to add bemotrizinol at concentrations up to 6 percent as a sunscreen active ingredient. A sunscreen drug product containing bemotrizinol is generally recognized as safe and effective (GRASE) if it meets the conditions described in OTC Monograph M020 as amended by this final order. DATES: The announcement of the availability on FDA's website of the final order is published in the Federal Register on June 10, 2026. Shannon Liu, Center for Drug Evaluation and Research (HFD-600), Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 240-402-2484, Shannon.Liu@fda.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background FDA is issuing final order OTC000039 to amend the requirements for sunscreen drug products for OTC human use, as described in OTC Monograph M020, to add bemotrizinol for use as a sunscreen active ingredient at concentrations up to 6 percent. FDA is issuing the final order pursuant to section 505G(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355h(b)(1)). OTC Monograph M020 describes the conditions under which OTC sunscreen drug products are GRASE under section 201(p)(1) of the FD&C Act (21 U.S.C. 321(p)(1)). OTC Monograph M020 was previously set forth in final order OTC000006, as deemed by sections 505G(b)(8) and 505G(k)(2)(B) of the FD&C Act, and was effective upon enactment of the Coronavirus Aid, Relief, and Economic Security Act (Pub. L. 116-136) on March 27, 2020. The conditions described in OTC Monograph M020 may be amended, revoked, or otherwise modified in accordance with the procedures of section 505G(b) of the FD&C Act. On September 23, 2024, DSM Nutritional Products LLC submitted a Tier 1 OMOR requesting FDA issue an administrative order finding that a sunscreen drug product containing bemotrizinol as an active ingredient is GRASE under the conditions described in OTC Monograph M020. Final order OTC000039 amends the conditions described in OTC Monograph M020, as set forth in final order OTC000006, to add bemotrizinol at concentrations up to 6 percent as a sunscreen active ingredient. The final ( printed page 35221) order establishes that for a sunscreen drug product containing bemotrizinol as a sunscreen active ingredient to be legally marketed without an approved application under section 505 of the FD&C Act (21 U.S.C. 355), among other requirements, it must conform to certain conditions that address the concentration of bemotrizinol in the sunscreen drug product, permitted combinations of bemotrizinol with other sunscreen active ingredients and with skin protectant active ingredients, and permitted dosage forms. Specific to dosage forms, the final order permits sunscreen drug products containing bemotrizinol to be in the following dosage forms: oil, lotion, cream, gel, butter, paste, ointment, stick, and spray, provided that the sunscreen drug product in spray dosage form is manufactured and packaged with no propellant or is manufactured and packaged in a spray delivery system where all propellant is isolated from the drug product formulation within the container closure system, and there is no contact between the propellant and the drug product formulation. Final order OTC000039 also includes minor stylistic and formatting changes to improve the readability, clarity, and presentation of OTC Monograph M020. A notice of availability of the proposed order titled “Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use” was announced in the Federal Register on December 12, 2025 (90 FR 57765). FDA considered timely submitted comments on the proposal to amend OTC Monograph M020 to add bemotrizinol as a sunscreen active ingredient. After considering comments, FDA did not make changes to the final order. II. Paperwork Reduction Act of 1995 Final order OTC000039 is issued under section 505G(b)(1) of the FD&C Act. Under section 505G(o) of the FD&C Act, the Paperwork Reduction Act of 1995 (Chapter 35 of title 44, United States Code) does not apply to collections of information made under section 505G of the FD&C Act. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required for collections of information, if any, in a final order issued under section 505G. III. Electronic Access The final order can be accessed on the OTC Monographs@FDA portal at https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm. Under the “Administrative Orders” banner, click on the desired link under the “Order ID” heading and follow the prompts. FDA established this information technology system with a web portal that can be accessed through FDA's website. The OTC Monographs@FDA portal provides a resource for the public to view administrative orders (proposed, final, and interim final orders), as well as related supporting documents, for OTC Monograph Drugs and view OTC Monographs. In the future, the OTC Monographs@FDA portal will facilitate the public's ability to submit, search, and view comments and data for proposed and interim final orders. Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.